Radiopharmaceutical developer Navidea Biopharmaceuticals has signed an agreement with biopharmaceutical company IMV to explore a preclinical research collaboration that could combine each company's immunotherapy technologies.
The goal of the collaboration is to perform preclinical research studies that evaluate the combination of Navidea's CD206-activated macrophage-targeting therapeutics with IMV's DPX-based immunotherapies. Both companies will jointly conduct the research throughout the duration of the study.
The companies believe the joint research could lead to new approaches to treating a variety of cancers.
